For the quarter ended September 2024, Organon (OGN) reported income of $1.58 billion, up 4.2% over the identical interval final 12 months. EPS got here in at $0.87, in comparison with $0.87 within the year-ago quarter.
The reported income compares to the Zacks Consensus Estimate of $1.56 billion, representing a shock of +1.37%. The corporate delivered an EPS shock of +2.35%, with the consensus EPS estimate being $0.85.
Whereas buyers carefully watch year-over-year modifications in headline numbers — income and earnings — and the way they examine to Wall Road expectations to find out their subsequent plan of action, some key metrics all the time present a greater perception into an organization’s underlying efficiency.
Since these metrics play an important position in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps buyers higher venture a inventory’s value efficiency.
Right here is how Organon carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Income- Ladies’s Well being- U.S.- Nexplanon/Implanon NXT: $172 million versus $164.46 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +17.8% change.
- Geographic Income- U.S. $398 million versus $400.64 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +7.6% change.
- Income- Ladies’s Well being- U.S.- NuvaRing: $7 million versus $10.08 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -61.1% change.
- Income- Ladies’s Well being- U.S.- Follistim AQ: $26 million versus $25.52 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +18.2% change.
- Income- Ladies’s Well being- Nexplanon/Implanon NXT: $243 million in comparison with the $238.19 million common estimate based mostly on three analysts. The reported quantity represents a change of +10.5% 12 months over 12 months.
- Income- Ladies’s Well being- Follistim AQ: $63 million versus the three-analyst common estimate of $66.32 million. The reported quantity represents a year-over-year change of +16.7%.
- Income- Biosimilars Whole: $165 million in comparison with the $168.58 million common estimate based mostly on three analysts. The reported quantity represents a change of +16.2% 12 months over 12 months.
- Income- Ladies?s Well being Whole: $440 million versus $452.30 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +5.3% change.
- Income- Different Whole: $26 million in comparison with the $25.20 million common estimate based mostly on three analysts. The reported quantity represents a change of +8.3% 12 months over 12 months.
- Income- Established Manufacturers- Non-Opioid Ache, Bone and Dermatology- Different: $74 million versus $73.71 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a 0% change.
- Income- Ladies’s Well being- NuvaRing: $23 million versus $28.12 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -37.8% change.
- Income- Biosimilars- Renflexis: $72 million in comparison with the $67.30 million common estimate based mostly on three analysts. The reported quantity represents a change of +4.4% 12 months over 12 months.
View all Key Company Metrics for Organon here>>>
Shares of Organon have returned -3.5% over the previous month versus the Zacks S&P 500 composite’s +1% change. The inventory presently has a Zacks Rank #3 (Maintain), indicating that it may carry out in step with the broader market within the close to time period.
5 Shares Set to Double
Every was handpicked by a Zacks professional because the #1 favourite inventory to achieve +100% or extra in 2024. Whereas not all picks may be winners, earlier suggestions have soared +143.0%, +175.9%, +498.3% and +673.0%.
A lot of the shares on this report are flying below Wall Road radar, which gives an excellent alternative to get in on the bottom ground.
Today, See These 5 Potential Home Runs >>
Organon & Co. (OGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
